<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044509</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Therapeutic options for patients uit localized prostatic carcinoma: our experience with 454 patients</dc:title>
<dc:description xml:lang="en">OBJECTIVES: To evaluate the influence of different therapeutic options on progression-free survival (PFS), overall survival (OS) and specific survival (SS) in a cohort of 454 patients with localized prostatic carcinoma, taking into account different prognostic factors, and to compare our results to those reported in the world literature. MATERIAL AND METHODS: Between 1983 and 2000 we have diagnosed 706 new cases of prostatic carcinoma and 454 were clinically localized tumors. The different therapeutic options employed in our series of patients have been: follow-up (FU) (103 patients); radical prostatectomy (RP) (108 patients); radiotherapy without hormonal blockade (RT) (148 patients); and hormonal blockade (HB) (95 patients). We have determined the PFS, the OS and the SS for each group of patients and compared them in patients with different prognostic factors at the time of diagnosis, including age, PSA levels, Gleason&#146;s grading and TNM staging. We have also analysed the influence of the tumor progression on the OS. The mean follow-up time has been 5.6 years (range: 0.1-19.2; median: 5.2). RESULTS: For PFS: the disease progressed in 145 patients (32%) and the PFS at 5 and 10 years has been 77% and 67% for FU; 61% and 50% for RP; 63% and 25% for RT; and 73% and 67% for HB, respectively. The differences between RT and RP were not statistically significant. For the subgroup of patients with PSA levels &lt;10 and Gleason &lt;8 the differences between FU, RP and RT did not reach statistical significance. For OS: 126 patients of our series died (28%) and the OS at 5 and 10 years has been 80% and 61% for FU; 90% and 76% for RP; 85% and 67% for RT; and 64% and 32% for HB, respectively. We have found no significant differences between FU, RPand RT. For SS: 31 patients of our series died of disease (6.8%). The SS at 5 and 10 years has been 100% and 94% for FU; 98% and 98% for RP; 97% and 88% for RT; and 83% and 77% for HB, respectively. We have found no significant differences in the OS between patients with disease progression and without disease progression treated with FU, RP and RT. CONCLUSIONS: Determination of PSA levels has allowed diagnosis of prostatic carcinomas in early stages of disease; however, our results and those reported in the literature cannot define which is the best therapeutic option in these patients. We should offer the patients individualized information both in the phase of early diagnosis and of therapeutic decisions</dc:description>
<dc:creator>García González, J. I</dc:creator>
<dc:creator>Arrizabalaga Moreno, M</dc:creator>
<dc:creator>Pérez Garnelo, M. J</dc:creator>
<dc:creator>Paniagua Andrés, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVOS: Evaluar en una cohorte de 454 pacientes con cáncer de próstata no diseminado tratados con diversas alternativas terapéuticas la supervivencia libre de progresión (SLP), supervivencia global (SG) y supervivencia específica (SE) en función de distintos factores pronósticos y comparar nuestros resultados con la bibliografía. MATERIAL Y MÉTODOS: Entre 1983 y 2000 hemos diagnosticado 706 pacientes de cáncer de próstata, de los que 454 eran clínicamente tumores no diseminados. Los tratamientos utilizados para estos 454 pacientes han sido: observación (OBS) (103 pacientes), prostatectomía radical (PR) (108), radioterapia no asociada a tratamiento hormonal (RT) (148) y bloqueo hormonal (BH) (95). Hemos analizado la SLP, SG y SE en cada grupo y comparativamente en función de distintos factores pronósticos en el momento del diagnóstico: edad, PSA, Gleason y estadio. También analizamos la repercusión de la progresión en la SG. El seguimiento medio ha sido de 5,6 años (0,1-19,2 años; mediana 5,2). RESULTADOS: SLP: han progresado 145 pacientes (32%), a 5 años la SLP para OBS: 77%, PR: 61%, RT: 63%, BH: 73%. A 10 años: 67, 50, 25 y 67%, respectivamente. No diferencias significativas entre PR y RT. En pacientes con PSA &lt;10 y Gleason &lt;8 no diferencias entre OBS, PR y RT. SG: han fallecido 126 pacientes (28%), a 5 años la SG fue: 80, 90, 85 y 64% y a 10 años: 61, 76, 67 y 32%. No diferencias entre OBS, PR y RT. SE: han fallecido por su tumor 31 (6,8%). SE a 5 años: 100, 98, 97 y 83%. A 10 años: 94, 98, 88 y 77%. No diferencias en la SG entre los pacientes en progresión comparados con los pacientes sin progresión tumoral en los tratados con OBS, PR y RT. CONCLUSIONES: La determinación del antígeno PSA ha trasladado el diagnóstico del cáncer de próstata a estadios muy precoces, sin embargo nuestros datos y la revisión de la bibliografía no permiten definir cual es la mejor estrategia terapéutica incluyendo la alternativa observacional. Debemos dar la suficiente información individualizada tanto en la fase de diagnóstico precoz como a la hora de decidir un tratamiento</dc:description>
<dc:source>Actas Urol Esp;28(6): 418-431, jun. 2004. tab, graf</dc:source>
<dc:identifier>ibc-044509</dc:identifier>
<dc:title xml:lang="es">Alternativas terapéuticas en el cáncer de próstata localizado. Experiencia sobre 454 pacientes</dc:title>
<dc:subject>^d28620</dc:subject>
<dc:subject>^d23947^s22073</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d27977</dc:subject>
<dc:subject>^d34537^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d11914^s22057</dc:subject>
<dc:subject>^d11914^s22067</dc:subject>
<dc:subject>^d11911^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:subject>^d11914^s22059</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200406</dc:date>
</metadata>
</record>
</ibecs-document>
